Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Archive

A Bone Marrow Transplantation at Hadassah Cures Child of Severe Blood Disorder

Eleven-year-old Fatma,* a Palestinian young girl suffering from the serious blood disorder, thalassemia major, received a bone marrow transplantation at the Hadassah University Medical Center and was cured of this debilitating disease.

Thalassemia major, which results in a serious deficiency in the production of hemoglobin and, therefore, severe anemia, caused Fatma to need blood transfusions every three or four weeks. These life-saving blood transfusions can cause another problem: the iron in the transfused blood gets deposited in organs of the body and can result in damage to the heart. Therefore, Fatma also had to endure ongoing treatments to rid her body of the extra iron.

"In some cases," explains Dr. Michael Weintraub, Director of Hadassah's Pediatric Hematology-Oncology Department, "parents who have a child with a chronic illness choose to continue conventional treatment, while praying that a cure will be discovered." Fatma's parents, however, made a different choice. They decided on bone marrow transplantation.

Once a donor was found, Fatma underwent the procedure at Hadassah. While the transplant proved successful, she developed the rare severe complication of Guillain-Barré syndrome, a disorder that causes paralysis within the peripheral nervous system. Consequently, she was transferred to the Pediatric Intensive Care Unit (PICU), where she spent several weeks. She was connected to a ventilator, underwent a tracheotomy and, slowly, she recovered. Now she is disease-free!

Partner with Hadassah to save other children like Ilana.

 

*named changed to protect the patient's privacy

Date: 11/14/2011


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America